A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
Status:
Completed
Trial end date:
2017-05-20
Target enrollment:
Participant gender:
Summary
The initial proposed clinical study will be conducted in adult head and neck cancer subjects.
This will be an open-labeled, proof of concept trial to evaluate the efficacy, safety and
tolerability of EISO in a form of oral rinse as adjunctive therapy to standard of care.
Santalis believes that the proposed study is a prudent and appropriate approach to
investigate the potential of their product to prevent or improve oral mucositis symptoms
commonly seen in subjects undergoing radiotherapy with or without chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Santalis Pharmaceuticals, Inc.
Collaborator:
The University of Texas Health Science Center at San Antonio